{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA103606
(1996)
Source URL:
First approved in 1996
Source:
BLA103606
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Imovax Polio by Sanofi Pasteur Limited [Canada]
Source URL:
First approved in 1990
Source:
BLA103930
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Imovax Polio by Sanofi Pasteur Limited [Canada]
Source URL:
First approved in 1990
Source:
BLA103930
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Imovax Polio by Sanofi Pasteur Limited [Canada]
Source URL:
First approved in 1990
Source:
BLA103930
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02445703: Phase 4 Interventional Completed Hepatitis A
(2014)
Source URL:
Class:
STRUCTURALLY DIVERSE